Wall Street Zen Upgrades DaVita (NYSE:DVA) to Buy

Key Points

• Wall Street Zen upgraded DaVita from “hold” to “buy,” while broader analyst sentiment remains “Moderate Buy” with a consensus price target of $233.43.
• DaVita reported quarterly EPS of $4.02, beating estimates of $3.88, while revenue reached $3.55 billion and rose 5.2% year over year.
• Institutional ownership is substantial at 90.12%; Berkshire Hathaway acquired an approximately $6.43 billion stake, alongside major purchases by BlackRock and other financial institutions.

DaVita (NYSE:DVA - Get Free Report) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Several other research firms have also recently issued reports on DVA. Raymond James Financial set a $220.00 price target on DaVita in a research note on Friday, August 7th. Zacks Research cut shares of DaVita from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 6th. UBS Group upped their price objective on shares of DaVita from $235.00 to $270.00 and gave the stock a "buy" rating in a report on Friday, July 10th. Barclays increased their target price on shares of DaVita from $218.00 to $224.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 5th. Finally, Oppenheimer set a $220.00 target price on shares of DaVita in a research note on Friday, August 7th. Four equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $233.43.

DaVita Stock Down 1.1%

Shares of NYSE:DVA opened at $187.16 on Friday. The company's 50-day moving average price is $180.47 and its 200 day moving average price is $190.56. The company has a market cap of $11.94 billion, a PE ratio of 15.32, a P/E/G ratio of 0.49 and a beta of 0.80. DaVita has a fifty-two week low of $101.00 and a fifty-two week high of $247.49.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, beating the consensus estimate of $3.88 by $0.14. The company had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. DaVita's revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the business earned $2.95 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities analysts anticipate that DaVita will post 14.57 EPS for the current year.

Institutional Trading of DaVita

Institutional investors and hedge funds have recently bought and sold shares of the stock. Berkshire Hathaway Inc acquired a new stake in shares of DaVita during the second quarter valued at approximately $6,425,269,000. BlackRock Inc. purchased a new stake in shares of DaVita in the second quarter valued at $547,520,000. Bank of America Corp DE purchased a new stake in shares of DaVita in the second quarter valued at $145,057,000. Bank of New York Mellon Corp acquired a new stake in shares of DaVita in the second quarter worth $101,127,000. Finally, Deutsche Bank AG acquired a new stake in shares of DaVita in the second quarter worth $46,356,000. Institutional investors and hedge funds own 90.12% of the company's stock.

DaVita Company Profile

DaVita Inc is a healthcare company focused on kidney care and renal disease management. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with end-stage kidney disease, including hemodialysis and peritoneal dialysis, as well as home dialysis support.

The company also operates hospital-based dialysis programs and offers clinical, administrative and care-coordination services intended to support patients across the kidney-care journey.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.